Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Technology Report
  • Published:

Biotechnology Trade with Japan

Bio/Technology volume 2, pages 327–332 (1984)Cite this article

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Pharmaceutical Administration in Japan, 2nd ed. Pharmaceutical Affairs Bureau, Ministry of Health and Welfare of Japan, Tokyo. February 1980.

  2. Commercial Biotechnology: An International Analysis. U.S. Congress Office of Technology Assessment, OTA-BA218, Washington D.C. January 1984.

  3. Yakuji Handobukku 1983 (Drug Industry Handbook 1983). Yakugyo Jiho Co., Tokyo, p. 21–23.

  4. Nihon Shoken Shimbun. 1982. Jisei-dai no Shinyaku Kaihatsu to Kanren Kigyo (Next generation drug development and related firms). Nihon Shoken Shimbunsha, Tokyo.

  5. Lohr, S . 1983. Merck's big venture in Japan. N.Y. Times, New York. 13 October 1983.

  6. Anon. 1984. CIBA-Geigy Japan dropping marketing deals. Japan Economic J. 22: 15.

  7. Handling of foreign test data and Japanese GLP 1982. Pharmaceutical Affairs Bureau, Ministry of Health and Welfare of Japan. Yakugyo Jiho Co., Tokyo. 1982.

  8. Measures Taken by the Japanese Ministry of Health and Welfare (MHW) for Further Opening the Japanese Market Regarding Pharmaceuticals, Food, and So Forth. Ministry of Health and Welfare of Japan, Tokyo. April 1983.

  9. Government to approve imports of viral hepatitis vaccine. Japan Times, Tokyo. 29 May 1983.

  10. Ministry of Health and Welfare to allow import of hepatitis vaccine. Tokyo Shimbun, Tokyo. 29 May 1983.

  11. Anon. 1984. B hepatitis vaccine project. Japan Economic J. 22: 16.

Download references

Author information

Author notes

  1. Amelia Porges is an assistant general counsel in the Office of the U.S. Trade Representative, Executive Office of the President, Washington, D.C. 20506. The views and opinions expressed herein are solely those of the author and do not necessarily reflect the views and policies of the Office of the U.S. Trade Representative or the U.S. government.

    • Amelia Porges
Authors
  1. Amelia Porges
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Porges, A. Biotechnology Trade with Japan. Nat Biotechnol 2, 327–332 (1984). https://doi.org/10.1038/nbt0484-327

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0484-327

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing